Genmab A/S (NASDAQ:GMAB) Shares Gap Up – Should You Buy?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares gapped up before the market opened on Tuesday . The stock had previously closed at $26.02, but opened at $27.96. Genmab A/S shares last traded at $27.73, with a volume of 727,351 shares trading hands.

Analyst Ratings Changes

A number of research firms recently weighed in on GMAB. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Wolfe Research initiated coverage on Genmab A/S in a research report on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective for the company. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Finally, Truist Financial assumed coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.93.

Genmab A/S Stock Performance

The company has a market capitalization of $17.23 billion, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 1.77 and a beta of 0.84. The firm has a 50 day moving average price of $26.15 and a two-hundred day moving average price of $28.69. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18.

Institutional Trading of Genmab A/S

Institutional investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC raised its stake in Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares in the last quarter. NewEdge Advisors LLC boosted its stake in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Genmab A/S in the 1st quarter valued at $34,000. Brown Brothers Harriman & Co. grew its holdings in shares of Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the last quarter. Finally, Founders Capital Management increased its position in shares of Genmab A/S by 40.0% during the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.